острый миелобластный лейкозаутологичная трансплантация гемопоэтических стволовых клетоктотальное терапевтическое облучениефакторы неблагоприятного прогноза1.1. Miller K. B., Pihan G. et al. Clinical manifestations of acute myeloid leukemia. In: Hematology. Basic Principles and Practice. 5th edn. Ed. by R. Hoffman, E. J. Benz, J. S. Shattil et al. New York: Churchill Livingstone, 2009. Pp. 933–63.Miller K. B., Pihan G. et al. Clinical manifestations of acute myeloid leukemia. In: Hematology. Basic Principles and Practice. 5th edn. Ed. by R. Hoffman, E. J. Benz, J. S. Shattil et al. New York: Churchill Livingstone, 2009. Pp. 933–63.2.2. Meshinchi S., Appelbaum F. R. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 2009;15(13):4263–9.Meshinchi S., Appelbaum F. R. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 2009;15(13):4263–9.3.3. Sitnicka E., Buza-Vidas N., Larsson S. et al. Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 2003;102(3):881–6.Sitnicka E., Buza-Vidas N., Larsson S. et al. Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 2003;102(3):881–6.4.4. Маркина И. Г., Тупицын Н. Н., Волкова М. А., Френкель М. А. Влияние иммунофенотипа бластных клеток на прогноз острого нелимфобластного лейкоза. Вестник РОНЦ им. Н. Н. Блохина РАМН 2000;2(11):30–6. [Markina I. G., Tupitsyn N. N., Volkova M. A., Frenkel’ M. A. Influence of immunophenotype of blast cells on the prognosis of acute nonlymphoblastic leukemia. Vestnik RONC im. N. N. Blokhina RAMN = Bulletin of N. N. Blokhin RCRС of RAMS 2000;2(11):30–6. (In Russ.)].Маркина И. Г., Тупицын Н. Н., Волкова М. А., Френкель М. А. Влияние иммунофенотипа бластных клеток на прогноз острого нелимфобластного лейкоза. Вестник РОНЦ им. Н. Н. Блохина РАМН 2000;2(11):30–6. [Markina I. G., Tupitsyn N. N., Volkova M. A., Frenkel’ M. A. Influence of immunophenotype of blast cells on the prognosis of acute nonlymphoblastic leukemia. Vestnik RONC im. N. N. Blokhina RAMN = Bulletin of N. N. Blokhin RCRС of RAMS 2000;2(11):30–6. (In Russ.)].5.5. Тупицын Н. Н., Попа А. В., Маркина И. Г. Клиническое значение иммунофенотипа острых миелобластных лейкозов. Гематология и трансфузиология 1999;(3):3–8. [Tupitsyn N. N., Popa A. V., Markina I. G. The clinical significance of immunophenotype in acute myeloid leukemia. Gematologiya i transfuziologiya = Hematology and Transfusiology 1999;(3):3–8. (In Russ.)].Тупицын Н. Н., Попа А. В., Маркина И. Г. Клиническое значение иммунофенотипа острых миелобластных лейкозов. Гематология и трансфузиология 1999;(3):3–8. [Tupitsyn N. N., Popa A. V., Markina I. G. The clinical significance of immunophenotype in acute myeloid leukemia. Gematologiya i transfuziologiya = Hematology and Transfusiology 1999;(3):3–8. (In Russ.)].6.6. Munker R., Hildebrandt G. C., Atkinson K. Therapeutic decision making in BMT/SCT for acute myeloid leukemia. In: The BMT data book. Including cellular therapy. 3rd edn. Ed. by R. Munker, G. C. Hildebrandt, H. M. Lazarus, K. Atkinson. New York: Cambridge University Press, 2013. Pp. 25–40.Munker R., Hildebrandt G. C., Atkinson K. Therapeutic decision making in BMT/SCT for acute myeloid leukemia. In: The BMT data book. Including cellular therapy. 3rd edn. Ed. by R. Munker, G. C. Hildebrandt, H. M. Lazarus, K. Atkinson. New York: Cambridge University Press, 2013. Pp. 25–40.7.7. Программное лечение заболеваний системы крови. Под ред. В. Г. Савченко. М.: Практика, 2012. С. 153–207. [Protocol treatment of blood diseases. Ed. by V. G. Savchenko. Moscow: Praktika, 2012. Pp. 153–207. (In Russ.)].Программное лечение заболеваний системы крови. Под ред. В. Г. Савченко. М.: Практика, 2012. С. 153–207. [Protocol treatment of blood diseases. Ed. by V. G. Savchenko. Moscow: Praktika, 2012. Pp. 153–207. (In Russ.)].8.8. Sureda A., Bader P., Cesaro S. et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015;50(8):1037–56.Sureda A., Bader P., Cesaro S. et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015;50(8):1037–56.9.9. NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Acute Mueloid Leukemia. v. 1.2015.NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Acute Mueloid Leukemia. v. 1.2015.10.10. Cassileth P. A., Harrington D. P., Appelbaum F. R. et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339(23):1649–56.Cassileth P. A., Harrington D. P., Appelbaum F. R. et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339(23):1649–56.11.11. Munker R., Lazarus H. M., Atkinson K. The BMT data book. 2nd edn. 2009. 32 р.Munker R., Lazarus H. M., Atkinson K. The BMT data book. 2nd edn. 2009. 32 р.12.12. Lazarus H. M., Pérez W. S., Klein J. P. et al. Autotransplantation versus HLAmatched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006;132(6):755–69.Lazarus H. M., Pérez W. S., Klein J. P. et al. Autotransplantation versus HLAmatched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006;132(6):755–69.13.13. Munker R., Hildebrandt G. C., Lazarus H. M. The BMT data book. 3rd edn. 2013. 37 р.Munker R., Hildebrandt G. C., Lazarus H. M. The BMT data book. 3rd edn. 2013. 37 р.14.14. Vellenga E., van Putten W., Ossenkoppele G. J. et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011;118(23):6037–42.Vellenga E., van Putten W., Ossenkoppele G. J. et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011;118(23):6037–42.15.15. Burnett A. K., Goldstone A. H., Stevens R. M. et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children’s Leukaemia Working Parties. Lancet 1998;351(9104):700–8.Burnett A. K., Goldstone A. H., Stevens R. M. et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children’s Leukaemia Working Parties. Lancet 1998;351(9104):700–8.16.16. Wetzel D., Mueller B. U., Mansouri Taleghani B. et al. Delayed haematological recovery after autologous stem cell transplantation is associated with favorable outcome in acute myeloid leukaemia. Br J Haematol 2015;168(2):268–73.Wetzel D., Mueller B. U., Mansouri Taleghani B. et al. Delayed haematological recovery after autologous stem cell transplantation is associated with favorable outcome in acute myeloid leukaemia. Br J Haematol 2015;168(2):268–73.17.17. Thomas E. D., Clift R. A., Hersman J. et al. Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys 1982;8(5): 817–21.Thomas E. D., Clift R. A., Hersman J. et al. Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys 1982;8(5): 817–21.18.18. Tutschka P. J., Copelan E. A., Klein J. P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987;70(5):1382–8.Tutschka P. J., Copelan E. A., Klein J. P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987;70(5):1382–8.19.19. Mollee P., Gupta V., Song K. Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia. Bone Marrow Transplant 2004;33(12):1201–8.Mollee P., Gupta V., Song K. Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia. Bone Marrow Transplant 2004;33(12):1201–8.20.20. Абдусаламов С. Н., Мелкова К. Н., Чернявская Т. З. и др. Градация интенсивности и подходы к оптимизации сопроводительной терапии при трансплантации костного мозга. Клиническая онкогематология 2009;2(4):334–42. [Abdusalamov S. N., Melkova K. N., Chernyavskaya T. Z. et al. Gradation of intensity and approaches to optimizing supportive care in bone marrow transplantation. Klinicheskaya onkogematologiya = Clinical Oncohematology 2009;2(4):334–42. (In Russ.)].Абдусаламов С. Н., Мелкова К. Н., Чернявская Т. З. и др. Градация интенсивности и подходы к оптимизации сопроводительной терапии при трансплантации костного мозга. Клиническая онкогематология 2009;2(4):334–42. [Abdusalamov S. N., Melkova K. N., Chernyavskaya T. Z. et al. Gradation of intensity and approaches to optimizing supportive care in bone marrow transplantation. Klinicheskaya onkogematologiya = Clinical Oncohematology 2009;2(4):334–42. (In Russ.)].21.21. Абдусаламов С. Н., Мелкова К. Н., Горбунова Н. В. и др. Профилактические режимы ведения больных и подходы к оптимизации сопроводительной терапии при трансплантации костного мозга. Клиническая онкогематология 2010;3(1):21–9. [Abdusalamov S. N., Melkova K. N., Gorbunova N. V. et al. Prophylactic patient management and approaches to optimizing supportive care in bone marrow transplantation. Klinicheskaya onkogematologiya = Clinical Oncohematology 2010;3(1):21–9. (In Russ.)].Абдусаламов С. Н., Мелкова К. Н., Горбунова Н. В. и др. Профилактические режимы ведения больных и подходы к оптимизации сопроводительной терапии при трансплантации костного мозга. Клиническая онкогематология 2010;3(1):21–9. [Abdusalamov S. N., Melkova K. N., Gorbunova N. V. et al. Prophylactic patient management and approaches to optimizing supportive care in bone marrow transplantation. Klinicheskaya onkogematologiya = Clinical Oncohematology 2010;3(1):21–9. (In Russ.)].22.22. Wilson W. H., Jain V., Bryant G. et al. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 1992;10(11):1712–22.Wilson W. H., Jain V., Bryant G. et al. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 1992;10(11):1712–22.23.23. Мелкова К. Н., Петрова Г. Д. Материалы 41-го конгресса Европейского общества по трансплантации костного мозга. Клиническая онкогематология 2015;8(3):343–52. [Melkova K. N., Petrova G. D. Proceedings of the 41st Congress of the European Society of Bone Marrow Transplantation. Klinicheskaya onkogematologiya = Clinical Oncohematology 2015;8(3):343–52. (In Russ.)].Мелкова К. Н., Петрова Г. Д. Материалы 41-го конгресса Европейского общества по трансплантации костного мозга. Клиническая онкогематология 2015;8(3):343–52. [Melkova K. N., Petrova G. D. Proceedings of the 41st Congress of the European Society of Bone Marrow Transplantation. Klinicheskaya onkogematologiya = Clinical Oncohematology 2015;8(3):343–52. (In Russ.)].24.24. Румянцев А. Г., Варфоломеева С. Р., Грачев Н. С. и др. Принципы и инструменты доказательной медицины в детской гематологии/онкологии. Доктор.Ру 2015;10(111):6–13. [Rumyantsev A. G., Varfolomeeva S. R., Grachev N. S. et al. The principles of evidence-based medicine in pediatric hematology/oncology. Doctor.Ru 2015;10(111):6–13. (In Russ.)].Румянцев А. Г., Варфоломеева С. Р., Грачев Н. С. и др. Принципы и инструменты доказательной медицины в детской гематологии/онкологии. Доктор.Ру 2015;10(111):6–13. [Rumyantsev A. G., Varfolomeeva S. R., Grachev N. S. et al. The principles of evidence-based medicine in pediatric hematology/oncology. Doctor.Ru 2015;10(111):6–13. (In Russ.)].25.25. Apperley J., Carreras E., Gluckman E. et al. Haematopoietic stem cell transplantation. The EBMT Handbook. 5th edn. 2008.Apperley J., Carreras E., Gluckman E. et al. Haematopoietic stem cell transplantation. The EBMT Handbook. 5th edn. 2008.26.26. Zittoun R. A., Mandelli F., Willemze R. et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995;332(4): 217–23.Zittoun R. A., Mandelli F., Willemze R. et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995;332(4): 217–23.27.27. Isidori A., Bonifazi F., Visani G. et al. Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. Haematologica 2005;90(1):139–41.Isidori A., Bonifazi F., Visani G. et al. Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. Haematologica 2005;90(1):139–41.28.28. Sabty F. A., Demeckova E., Bojtarova E. et al. Is there still a role for autologous stem cell transplantation in acute myeloid leukemia? Neoplasma 2013;60(2):167–73.Sabty F. A., Demeckova E., Bojtarova E. et al. Is there still a role for autologous stem cell transplantation in acute myeloid leukemia? Neoplasma 2013;60(2):167–73.29.29. Martins C., Lacerda J. F., Lourenço F. et al. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience. Acta Med Port 2005;18(5):329–37.Martins C., Lacerda J. F., Lourenço F. et al. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience. Acta Med Port 2005;18(5):329–37.30.30. Dusenbery K. E., Daniels K. A., McClure J.S. et al. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys 1995;31(1):119–28.Dusenbery K. E., Daniels K. A., McClure J.S. et al. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys 1995;31(1):119–28.31.31. Мелкова К. Н., Горбунова Н. В., Чернявская Т. З. и др. Тотальное облучение организма человека при трансплантации костного мозга. Клиническая онкогематология 2012;5(2):96–114. [Melkova K. N., Gorbunova N. V., Chernyavskaya T. Z. et al. The total body irradiation in bone marrow transplantation. Klinicheskaya onkogematologiya = Clinical Oncohematology 2012;5(2):96–114. (In Russ.)].Мелкова К. Н., Горбунова Н. В., Чернявская Т. З. и др. Тотальное облучение организма человека при трансплантации костного мозга. Клиническая онкогематология 2012;5(2):96–114. [Melkova K. N., Gorbunova N. V., Chernyavskaya T. Z. et al. The total body irradiation in bone marrow transplantation. Klinicheskaya onkogematologiya = Clinical Oncohematology 2012;5(2):96–114. (In Russ.)].32.32. Hengeveld M., Suciu S., Chelgoum Y. High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT. Bone Marrow Transplant 2015;50(3):Hengeveld M., Suciu S., Chelgoum Y. High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT. Bone Marrow Transplant 2015;50(3):33.341–7.–7.34.33. Vellenga E., van Putten W. L., Boogaerts M. A. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? Bone Marrow Transplant 1999;23(12): 1279–82.Vellenga E., van Putten W. L., Boogaerts M. A. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? Bone Marrow Transplant 1999;23(12): 1279–82.35.34. Gorin N. C., Labopin M., Blaise D. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol 2009;27(24):3987–93.Gorin N. C., Labopin M., Blaise D. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol 2009;27(24):3987–93.36.35. Gorin N. C., Labopin M., Reiffers J. Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood 2010;116(17):3157–62.Gorin N. C., Labopin M., Reiffers J. Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood 2010;116(17):3157–62.